Cargando…

RAAS inhibition and mortality in hypertension

The renin-angiotensin-aldosterone system (RAAS) regulates the body's hemodynamic equilibrium, circulating volume, and electrolyte balance, and is a key therapeutic target in hypertension, the world's leading cause of premature mortality. Hypertensive disorders are strongly linked with an o...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ferrari, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963752/ https://www.ncbi.nlm.nih.gov/pubmed/24689028 http://dx.doi.org/10.5339/gcsp.2013.34

Ejemplares similares

Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients with Glomerulonephritis
por: Chin, Ho Jun, et al.
Publicado: (2011)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
por: Leoncini, Giovanna, et al.
Publicado: (2020)

Activation of RAAS Signaling Contributes to Hypertension in Aged Hyp Mice
por: Latic, Nejla, et al.
Publicado: (2022)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients
por: Vischer, Annina S., et al.
Publicado: (2021)

Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors
por: Rubio-Guerra, Alberto F, et al.
Publicado: (2009)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

TRPM8 and RAAS-mediated hypertension is critical for cold-induced immunosuppression in mice
por: Chan, Hao, et al.
Publicado: (2018)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
por: Garcia-Garduño, Texali C., et al.
Publicado: (2021)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19
por: Gupta, Neelesh, et al.
Publicado: (2020)

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
por: Dutsch, Alexander, et al.
Publicado: (2023)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Heavy Ion RAA summary Plots 2022
por: The ATLAS collaboration
Publicado: (2022)

Development and Application of RAA Nucleic Acid Test Strip Assay and Double RAA Gel Electrophoresis Detection Methods for ASFV and CSFV
por: Wu, Keke, et al.
Publicado: (2022)

Lifestyle-Induced Redox-Sensitive Alterations: Cross-Talk among the RAAS, Antioxidant/Inflammatory Status, and Hypertension
por: Szabó, Renáta, et al.
Publicado: (2021)

Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease
por: Monteonofrio, Laura, et al.
Publicado: (2020)

The RAAS Axis and SARS-CoV-2: From Oral to Systemic Manifestations
por: Maranduca, Minela Aida, et al.
Publicado: (2022)

Novel RAAS agonists and antagonists: clinical applications and controversies
por: Romero, Cesar A., et al.
Publicado: (2015)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19
por: Martín Giménez, Virna Margarita, et al.
Publicado: (2020)

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
por: Yuan, Yi-Ming, et al.
Publicado: (2015)

Genotype–phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome
por: Zhang, Yanqin, et al.
Publicado: (2021)

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
por: Cagnoni, Francesca, et al.
Publicado: (2010)

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
por: Hassani, Bahareh, et al.
Publicado: (2023)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

Heavy Ion Jet RAA Summary Plots 2023
por: The ATLAS collaboration
Publicado: (2023)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

RAAS inhibitors directly reduce diabetes‐induced renal fibrosis via growth factor inhibition
por: Koszegi, Sandor, et al.
Publicado: (2018)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney
por: Simeoni, Mariadelina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r160giqkld75a516o0mvkq6fkn